• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MARPAI, INC. REPORTS THIRD QUARTER 2022 RESULTS

    11/9/22 4:14:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email

    NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an AI-technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the third quarter ended September 30, 2022.

    The Company's consolidated results of operations include the results of operations of Marpai and its wholly owned subsidiary, Marpai Health, Inc., for all periods presented, and the results of Marpai Administrators, LLC (formerly Continental Benefits, LLC) since its acquisition on April 1, 2021.

    Financial Highlights

    • Net revenue of approximately $4.9 million for the three months ended September 30, 2022, compared to net revenue of approximately $5.6 million for the three months ended June 30, 2022, representing a sequential decrease of approximately $619,000, or 11.1%. This decline was caused by the third quarter decline in the number of our customers' employees covered under our plans.
    • The number of our customers' employees covered under the Company's administered health plans was 16,357, 21,074 and 21,139 on September 30, 2022, June 30, 2022, and March 31, 2022, respectively. As we explained on our second quarter earnings conference call, effective September 1, 2022, we decided not to renew the contracts of three customers who in our opinion were failing to fulfil their contractual obligations. These three customers accounted for more than 4,000 employees.
    • Operating expenses (including cost of revenues) were approximately $10.8 million for the three months ended September 30, 2022, as compared to approximately $12.2 million for the three months ended June 30, 2022, and approximately $11.8 million for the three months ended March 31, 2022.
    • Operating expenses (including cost of revenues) excluding stock based compensation expenses were approximately $10.1 million for the three months ended September 30, 2022 compared to approximately $11.1 million for the three months ended June 30, 2022, and approximately $11.1 million for the three months ended December 31, 2021.
    • Net loss was approximately $5.8 million for the three months ended September 30, 2022, compared to net loss of approximately $6.7 million for the three months ended June 30, 2022, and a net loss of approximately $5.5 million for the three months ended March 31, 2022.
    • Adjusted negative EBITDA was approximately $4.3 million for the three months ended September 30, 2022 compared to adjusted negative EBITDA of approximately $4.7 million for the three months ended June 30, 2022 and compared to adjusted negative EBITDA of approximately $4.0 million for the three months ended March 31, 2022. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

    Other Highlights

    On November 1, 2022, the Company announced the closing of the acquisition of Maestro Health, LLC ("Maestro Health") in a deal that more than doubles the size of the Company. Maestro Health is a leading TPA based in Chicago, Illinois that serves over 80 self-insured employers. Together, the joint company brings AI-powered health plan services to over 40,000 employees nationwide, making it the leading technology player in the market. The acquisition is expected to more than double the number of customers and members that Marpai serves.

    "Having closed the Maestro acquisition on October 31, we are now laser focused on the integration of the two companies, as well as our January 1, 2023 sales," said Edmundo Gonzalez, Chief Executive Officer of Marpai.

    Financial Guidance

    Due to the Maestro Health acquisition, which closed on October 31, 2022, we are not providing financial guidance for the fourth quarter at this time.

    Webcast and Conference Call Information

    Marpai will host a conference call and webcast tomorrow, on November 10, 2022 at 8:30 a.m. ET to answer questions about the Company's operational and financial highlights for its third quarter of 2022 as well as on the previously announced acquisition of Marpai Health.

    Investors interested in listening to the conference call may do so by dialing 1-800-289-0459 for domestic callers or +1-929-477-0443 for international callers, or by dialing 1-647-484-0473 for Canadian callers.

    The participant passcode to be used by the dialers is : 404193.  

    Investors can also listen via webcast: https://app.webinar.net/dPjlQJjQENW.

    For interested individuals unable to join the conference call, a recording of the webcast will also be available on the Marpai, Inc. investor relations website: https://ir.marpaihealth.com.

    About Marpai, Inc.

    Marpai, Inc. (NASDAQ:MRAI) is a technology company bringing AI-powered health plan services  to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA (Third Party Administrator) sector serving self-funded employer health plans representing over $1 trillion in annual claims, Marpai maximizes the value of the health plan as measured in health outcomes. Marpai takes a member-centric approach that uses AI and big data to connect members to health solutions predicted to have a high probability of positive outcomes, and aims to bring value-based care to the self-insured market. With effective early intervention, disease management, claims processing and proactive member outreach, Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release.

    Forward-Looking Statement Disclaimer

    This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding anticipated future results. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could," "will," "potential," "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the expected integration of Maestro Health and that the acquisition of Maestro Health is expected to double the size of the company and double the number of customers and members that Marpai serves.. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

    More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission (the "SEC"). Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov.

    Use of Non-GAAP Financial Measures and Their Limitations

    In addition to our results and measures of performance determined in accordance with U.S. GAAP presented in this press release, we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans and making strategic decisions.

    Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes.

    We believe that Adjusted EBITDA, together with a reconciliation to net loss, helps identify underlying trends in our business and helps investors make comparisons between our company and other companies that may have different capital structures, tax rates, or different forms of employee compensation. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to a key financial metric used by our management in its financial and operational decision-making. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these potential limitations include:

    • other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures;
    • although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements;
    • Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based compensation; and
    • Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt that we may incur.

    Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial measures.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and per share data)

    (unaudited)













    30-Sep

    31-Dec

    2022

    2021

    ASSETS







    Current assets:







     Cash and cash equivalents



    $             4,748

    $         19,183

     Restricted cash



    $             4,967

    $           6,751

     Accounts receivable



    191

    209

     Unbilled, receivable



    16

    15

     Prepaid expenses and other current assets



    366

    743

     Other current assets



    57

    91

        Total current assets



    10,345

    26,992









    Property and equipment, net



    737

    890

    Capitalized software, net



    5,411

    6,305

    Operating lease right-of-use assets



    1,526

    2,044

    Goodwill



    2,383

    2,383

    Intangible assets,net



    4,930

    5,508

    Security deposits



    52

    52

    Other long-term asset



    28

    28

         Total assets



    $          25,412

    $         44,202









    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)







    Current liabilities:







     Accounts payable



    $                693

    $           1,126

     Accrued expenses



    2,339

    2,525

     Accrued fiduciary obligations



    3,899

    5,541

     Deferred revenues



    871

    1,165

     Current portion of operating lease obligations



    846

    784

     Due to related party



    3

    4

              Total current liabilities



    8,651

    11,145









    Other long-term liabilities



    45

    45

    Operating lease liabilities, net of current portion



    728

    1,302

    Deferred tax liabilities



    2,001

    2,001

             Total liabilities



    11,425

    14,493









    Commitments and contingencies























    STOCKHOLDERS' EQUITY (DEFICIT)







     Common stock, $0.0001 par value, 227,791,050 shares authorized; 20,937,901  







         and 29,299,727 issued and outstanding at September, 2022 and

         December 31, 2021, respectively 

    2

    2

     Additional paid-in-capital



    53,445

    51,233

     Accumulated deficit



    (39,460)

    (21,526)

          Total stockholders' equity (deficit)



    13,987

    29,709

            Total liabilities & stockholders' equity (deficit)



    $          25,412

    $         44,202

     

    MARPAI, INC. AND SUBSIDIARIES



    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)

    (unaudited)















    Three Months Ended

    September 30,







    2022

    2021



    Revenues



    $         4,938

    $         4,799













    Costs and Expenses



















     Cost of revenue (exclusive of depreciation and 









       amortization shown separately below)



    $         3,625

    $         3,343



     General and Administrative



    $         2,718

    $         2,230



     Sales and Marketing



    $         1,054

    $         1,589



     Information Technology



    $         1,538

    $            770



     Research  and development



    $             782

    $            569



     Depreciation and amortization



    $             842

    $            802



     Facilities



    $             193

    $            232



     Loss on Disposal of Asset



    $                -

    $                -



              Total costs and expenses



    $       10,752

    $         9,535



         Operating Loss



    $        (5,814)

    $       (4,736)



    Other income (expenses)









     Interest expense , net



    $                (3)

    $           (109)



     Other income



    $               56

    $              55



     Foreign exchange loss



    $             (19)

    $               (3)



    (Loss) income before provision for income taxes



    $        (5,780)

    $       (4,793)



     Income tax benefit



    $                -

    $                -



         Net loss



    $        (5,780)

    $       (4,793)













    Net loss per share, basic & fully diluted (1)



    $          (0.28)

    $          (0.47)













    Weighted average number of common shares, basic



    20,348,655

    10,261,001



     and fully diluted (1)





















    (1) Reflects 4.55821-for-1 forward split that became effective September 2, 2021. The computation of basis and diluted net loss

         per share was retroatively adjusted for all periods presented . 







     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)

    (unaudited)













    Nine Months Ended

    September 30,





    2022

    2021

    Revenues



    $       16,713

    $         8,331









    Costs and Expenses















     Cost of revenue (exclusive of depreciation and 







      amortization shown separately below)



    $       12,324

    $         6,064

     General and Administrative



    $         7,940

    $         5,045

     Sales and Marketing



    $         4,830

    $         3,033

     Information Technology



    $         3,862

    $         1,501

     Research  and development



    $         2,684

    $         1,118

     Depreciation and amortization



    $         2,444

    $         1,223

     Facilities



    $             586

    $             459

     Loss on Disposal of Asset



    $               60

    $                -

              Total costs and expenses



    $       34,730

    $       18,443

         Operating Loss



    $      (18,017)

    $      (10,112)

    Other income (expenses)







     Interest expense , net



    $                (7)

    $           (385)

     Other income



    $               95

    $             110

     Foreign exchange loss



    $                (5)

    $             (19)

         (Loss) income before provision for income taxes



    $      (17,934)

    $      (10,406)

     Income tax benefit



    $                -

    $             150

         Net loss



    $      (17,934)

    $      (10,256)









    Net loss per share, basic & fully diluted (1)



    $          (0.90)

    $          (1.31)









    Weighted average number of common shares, basic



    20,019,116

    7,846,348

     and fully diluted (1)

















    (1) Reflects 4.55821-for-1 forward split that became effective September 2, 2021. The computation of basis and diluted net loss

         per share was retroatively adjusted for all periods presented . 





     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)















    Nine Months Ended 

    September 30,















    2022



    2021

    Cash flows (used in) operating activities













    Net loss













    $     (17,934)



    $     (10,256)

    Adjustments to reconcile net loss to net cash (used in) operating activities:









     Depreciation and amortization









    2,444



    1,224

     Share-based compensation









    60



    -

     Loss on disposal of assets









    2,464



    962

     Amortization of right-to-use asset









    517



    43

     Amortization of debt discount









    -



    27

     Non-cash interest











    -



    352

     Marketing services performed in exchange for convertible note





    -



    75

     Deferred Taxes















    (150)

     Changes in operating assets and liabilities:













       Accounts receivable and unbilled receivables







    16



    (245)

       Prepaid expenses and other assets









    377



    (381)

      Other receivables











    35



    50

      Accounts payable











    (433)



    1,566

      Accrued expenses











    (436)



    397

      Accrued fiduciary obligations









    (1,642)



    993

      Operating lease liabilities









    (512)



    (74)

      Other liabilities











    (295)



    (109)

         Net cash (used in ) operating activities







    (15,339)



    (5,526)





















    Cash flows from investing activities













     Cash and restricted cash acquired as part of acquisition 





    -



    11,384

     Capitalization of software development costs







    (810)



    (1,211)

     Purchase of property and equipment









    (70)



    (67)

         Net cash (used in)  investing activities







    (880)



    10,106





















    Cash flows from financing activities













    Proceeds from stock options exercises







    -



    -

    Proceeds from convertible notes









    -



    550

    Proceeds from short-term loan









    -



    2,000

    Proceeds from issuance of warrants









    -



    53

        Net cash provided by financing activities







    -



    2,053









































    Net increase in cash, cash equivalents and restricted cash



    (16,219)



    7,183

    Cash, cash equivalents and restricted cash at beginning of the period



    25,933



    1,818

    Cash, cash equivalents and restricted cash at end of period

    $

    9,714



    9,001





















    Reconciliation of cash, cash equivalents and restricted cash reported in the 







      condensed consolidated balance sheet













     Cash and cash equivalents









    $        4,748



    $          1,191

     Restricted cash











    4,966



    7,810

    Total cash, cash equivalents and restricted cash as shown in the 









      condensed consolidated balance sheet







    $        9,714



    $        9,001

     

    MARPAI, INC. AND SUBSIDIARIES

    RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA

    (in thousands)

    (unaudited)





    Three Months Ended



    Nine Months Ended

    September 30,

    September 30,





    2022

    2021



    2022

    2021















    Net Income (loss)



    $    (5,780)

    $     (4,793)



    $   (17,934)

    $  (10,257)

          Interest expense and foreign exchange loss, net



    $          (34)

    $            57



    $           (82)

    $         295

          Income tax benefit



    $             -

    $             -



    $             -

    $        (150)

         Disposal of asset



    $             -

    $             -



    $            60

    $             -

          Depreciation and amortization expense



    $         842

    $          802



    $       2,444

    $      1,223

          Stock based compensation expense



    $         697

    $          256



    $       2,464

    $         962















    Adjusted EBITDA



    $    (4,275)

    $     (3,678)



    $   (13,048)

    $    (7,927)

     

    Cision View original content:https://www.prnewswire.com/news-releases/marpai-inc-reports-third-quarter-2022-results-301673634.html

    SOURCE Marpai

    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSION

    Renews Aetna Signature Administrator Network Agreement and Enhances Cost Containment with Faircost Optimizer TAMPA, Fla., Dec. 1, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced significant positive momentum heading into the new year, highlighted by a better-than-expected sales cycle for 2026 and the renewal of its critical network access agreement with Aetna. The Company reports a robust sales cycle, securing a volume of new clients for January 1, 2026, that surpasses internal expectations, reinforcing its path to scalable growt

    12/1/25 4:04:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    SEC Filings

    View All

    Marpai Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement

    8-K - Marpai, Inc. (0001844392) (Filer)

    1/23/26 4:02:33 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    1/9/26 2:43:57 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    12/22/25 7:14:49 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Scrip Dallas was granted 100,000 shares (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:48:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

    STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

    1/22/25 5:00:00 PM ET
    $HIT
    $MRAI
    Specialty Insurers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care